echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > Vision loss and retinal changes in Stargardt disease

    Vision loss and retinal changes in Stargardt disease

    • Last Update: 2022-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    "These results provide a framework for assessing Stargardt disease progression, which will help control for significant differences between patients and facilitate treatment trials," said Michael F.


    About 1 in 9,000 people will develop the most common form of Stargardt or ABCA4-related retinopathy, an autosomal recessive disorder caused by mutations in the ABCA4 gene, which contains the genetic information for a transmembrane protein in photoreceptor cells


    However, even if all patients had the ABCA4 gene variant, there were large differences in age of onset and disease progression


    "Different variants of the ABCA4 gene may contribute to different disease features or phenotypes


    Using a retinal imaging technique called spectral domain optical coherence tomography (SD-OCT), the researchers followed 66 Stargardt patients (132 eyes) for five years


    Using deep learning, the researchers were able to quantify and compare the loss of photoreceptors and retinal layers based on patient phenotype and ABCA4 variation


    Specifically, the researchers focused on the health of a photoreceptor known as an ellipsoid zona -- a feature at the boundary between the inner and outer segments of a photoreceptor that weakens or disappears due to disease


    They found that the absence of ellipsoid regions (a measure of severe photoreceptor cell degeneration) and the thinning of the outer nuclear layer outside these regions (a measure of subtle photoreceptor cell degeneration) followed a predictable temporal and spatial patterns


    Importantly, they also found that photoreceptor degeneration was not limited to areas where the ellipsoid was lost


    "We now have structured outcome measures sensitive to Stargardt disease, applicable to a broad range of patients, which are critical to advancing therapeutic trials," Jeffrey said


    This research was funded by the NEI Intramural Research Program


    Journal Reference :

    1. Maximilian Pfau, Catherine A.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.